Skip to main content

CORRECTION article

Front. Oncol., 08 November 2022
Sec. Cancer Epidemiology and Prevention
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1072594

Corrigendum: The incidence risk of breast and gynecological cancer by antidepressant use: A systematic review and dose–response meta-analysis of epidemiological studies involving 160,727 patients

This article is a correction to:

  1. The incidence risk of breast and gynecological cancer by antidepressant use: A systematic review and dose–response meta-analysis of epidemiological studies involving 160,727 patients

    1. Read original article
Yanjia ZhuangYanjia Zhuang1Xiaogang Pang,Xiaogang Pang1,2Yuchen QiYuchen Qi3Tianshu ZhangTianshu Zhang1Guimao CaoGuimao Cao4Heming XueHeming Xue1Yifan Xu,Yifan Xu1,5Shuoxin Xie,Shuoxin Xie1,6Yifan Liu,Yifan Liu1,5Yinuo Wang,Yinuo Wang1,5Yunxiao Li,Yunxiao Li1,5Ying XiongYing Xiong7Yuanyuan Li*Yuanyuan Li1*Hui Shen*Hui Shen1*
  • 1Laboratory of Brain Science, Innovation Research Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
  • 2Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, China
  • 3School of health, Shandong University of Traditional Chinese Medicine, Jinan, China
  • 4Department of Anesthesiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
  • 5School of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
  • 6School of Acupuncture, Shandong University of Traditional Chinese Medicine, Jinan, China
  • 7Innovation Research Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China

A Corrigendum on
The incidence risk of breast and gynecological cancer by antidepressant use: A systematic review and dose–response meta-analysis of epidemiological studies involving 160,727 patients

by Zhuang Y, Pang X, Qi Y, Zhang T, Cao G, Xue H, Xu Y, Xie S, Liu Y, Wang Y, Li Y, Xiong Y, Li Y and Shen H (2022). Front. Oncol. 12:939636. doi: 10.3389/fonc.2022.939636

In the published article, there were three instances where there was a mistake in the cited references. This is because the references were renumbered sequentially after revision of manuscript.

In the Results section, the sentence “By comparison, a non-linear dose–response meta-analysis with 13 eligible studies (37-39, 42, 48, 55-57, 60, 61, 66, 83, 84)” has been changed to “By comparison, a non-linear dose–response meta-analysis with 13 eligible studies (37, 38, 42, 47, 48, 55-57, 60, 61, 66, 83, 84)”.

In the Results section, the sentence “Another negative linearity association also existed between the CDDD and the incidence risk of endometrial, corpus uteri, and cervical cancer, from four eligible studies (30, 33, 34, 72)” has been changed to “Another negative linearity association also existed between the CDDD and the incidence risk of endometrial, corpus uteri, and cervical cancer, from four eligible studies (28, 45, 49, 86)”.

In the Discussion section, the sentence “Moreover, different from several studies that have found that prolactin may encourage the development of estrogen receptor (ER)-positive tumors (89) and higher risk in in situ (51, 85)” has been changed to “Moreover, different from several studies that have found that prolactin may encourage the development of estrogen receptor (ER)-positive tumors (89) and higher risk in in situ (52, 85)”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: antidepressant, depression, breast cancer, gynecological cancer, Incidence, meta-analysis, systematic review, dose-response analysis

Citation: Zhuang Y, Pang X, Qi Y, Zhang T, Cao G, Xue H, Xu Y, Xie S, Liu Y, Wang Y, Li Y, Xiong Y, Li Y and Shen H (2022) Corrigendum: The incidence risk of breast and gynecological cancer by antidepressant use: A systematic review and dose–response meta-analysis of epidemiological studies involving 160,727 patients. Front. Oncol. 12:1072594. doi: 10.3389/fonc.2022.1072594

Received: 17 October 2022; Accepted: 25 October 2022;
Published: 08 November 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Zhuang, Pang, Qi, Zhang, Cao, Xue, Xu, Xie, Liu, Wang, Li, Xiong, Li and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hui Shen, aHVpc2hlbmxqQGhvdG1haWwuY29t; Yuanyuan Li, bHl5MDVfMjAxMkAxNjMuY29t

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.